A functional classification of ABCB4 variations causing progressive familial intrahepatic cholestasis type 3
暂无分享,去创建一个
C. Dossier | C. Housset | E. Jacquemin | M. Maurice | A. Durand‐Schneider | J. Delaunay | J. Gautherot | Tounsia Aït-Slimane | T. Falguières | A. Davit-Spraul | Thomas Falguières
[1] K. Lindor,et al. Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid. , 2015, Gastroenterology.
[2] J. Stindt,et al. A Mutation within the Extended X Loop Abolished Substrate-induced ATPase Activity of the Human Liver ATP-binding Cassette (ABC) Transporter MDR3* , 2014, The Journal of Biological Chemistry.
[3] C. Housset,et al. ABCB4: Insights from pathobiology into therapy. , 2014, Clinics and research in hepatology and gastroenterology.
[4] G. Bolbach,et al. AUTOIMMUNE, CHOLESTATIC AND BILIARY DISEASE Phosphorylation of ABCB4 Impacts Its Function: Insights From Disease-Causing Mutations , 2014 .
[5] P. Jara,et al. Functional analysis of ABCB4 mutations relates clinical outcomes of progressive familial intrahepatic cholestasis type 3 to the degree of MDR3 floppase activity , 2014, Gut.
[6] J. Boyer,et al. Peroxisome proliferator‐activated receptor α activates human multidrug resistance transporter 3/ATP‐binding cassette protein subfamily B4 transcription and increases rat biliary phosphatidylcholine secretion , 2014, Hepatology.
[7] M. Rastaldi,et al. Two ABCB4 point mutations of strategic NBD-motifs do not prevent protein targeting to the plasma membrane but promote MDR3 dysfunction , 2013, European Journal of Human Genetics.
[8] A. Cadoret,et al. Vitamin D Nuclear Receptor Deficiency Promotes Cholestatic Liver Injury by Disruption of Biliary Epithelial Cell Junctions in Mice , 2013, Hepatology.
[9] E. Jacquemin,et al. Clinical utility gene card for: Progressive familial intrahepatic cholestasis type 3 , 2013, European Journal of Human Genetics.
[10] P. Böelle,et al. Genotype‐phenotype relationships in the low‐phospholipid‐associated cholelithiasis syndrome: A study of 156 consecutive patients , 2013, Hepatology.
[11] T. Miyazaki,et al. AUTOIMMUNE , CHOLESTATIC , AND BILIARY DISEASE Anticholestatic Effects of Bezafibrate in Patients with Primary Biliary Cirrhosis Treated with Ursodeoxycholic Acid , 2013 .
[12] C. Housset,et al. Effects of Cellular, Chemical, and Pharmacological Chaperones on the Rescue of a Trafficking-defective Mutant of the ATP-binding Cassette Transporter Proteins ABCB1/ABCB4* , 2011, The Journal of Biological Chemistry.
[13] K. Linton,et al. Structure of ABC transporters. , 2011, Essays in biochemistry.
[14] F. Callea,et al. Two novel mutations in African and Asian children with progressive familial intrahepatic cholestasis type 3. , 2011, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.
[15] D. Consonni,et al. Clinical Features and Genotype-Phenotype Correlations in Children With Progressive Familial Intrahepatic Cholestasis Type 3 Related to ABCB4 Mutations , 2011, Journal of pediatric gastroenterology and nutrition.
[16] T. Pusl,et al. ABCB4 deficiency: A family saga of early onset cholelithiasis, sclerosing cholangitis and cirrhosis and a novel mutation in the ABCB4 gene , 2010, Hepatology research : the official journal of the Japan Society of Hepatology.
[17] D. Wendum,et al. Combined features of low phospholipid‐associated cholelithiasis and progressive familial intrahepatic cholestasis 3 , 2010, Liver international : official journal of the International Association for the Study of the Liver.
[18] E. Jacquemin,et al. A missense mutation in ABCB4 gene involved in progressive familial intrahepatic cholestasis type 3 leads to a folding defect that can be rescued by low temperature , 2009, Hepatology.
[19] Yue Weng,et al. Structure of P-Glycoprotein Reveals a Molecular Basis for Poly-Specific Drug Binding , 2009, Science.
[20] D. Clarke,et al. Mutational analysis of ABC proteins. , 2008, Archives of biochemistry and biophysics.
[21] M. Ziol,et al. ABCB4 heterozygous gene mutations associated with fibrosing cholestatic liver disease in adults. , 2008, Gastroenterology.
[22] A. Floreani,et al. Hepatobiliary phospholipid transporter ABCB4, MDR3 gene variants in a large cohort of Italian women with intrahepatic cholestasis of pregnancy. , 2008, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.
[23] M. Seia,et al. Molecular characterization and structural implications of 25 new ABCB4 mutations in progressive familial intrahepatic cholestasis type 3 (PFIC3) , 2007, European Journal of Human Genetics.
[24] K. Yoshizato,et al. Bezafibrate induces multidrug‐resistance P‐Glycoprotein 3 expression in cultured human hepatocytes and humanized livers of chimeric mice , 2007, Hepatology research : the official journal of the Japan Society of Hepatology.
[25] D. Clarke,et al. Transmembrane segment 7 of human P-glycoprotein forms part of the drug-binding pocket. , 2006, The Biochemical journal.
[26] M. Haberl,et al. Genetic Variability, Haplotype Structures, and Ethnic Diversity of Hepatic Transporters MDR3 (ABCB4) and Bile Salt Export Pump (ABCB11) , 2006, Drug Metabolism and Disposition.
[27] P. Meier,et al. BSEP and MDR3 haplotype structure in healthy Caucasians, primary biliary cirrhosis and primary sclerosing cholangitis , 2004, Hepatology.
[28] P. Meier,et al. Sequence analysis of bile salt export pump (ABCB11) and multidrug resistance p-glycoprotein 3 (ABCB4, MDR3) in patients with intrahepatic cholestasis of pregnancy. , 2004, Pharmacogenetics.
[29] R. Blevins,et al. Farnesoid X Receptor Activates Transcription of the Phospholipid Pump MDR3* , 2003, Journal of Biological Chemistry.
[30] Bryan Goodwin,et al. Hepatoprotection by the farnesoid X receptor agonist GW4064 in rat models of intra- and extrahepatic cholestasis. , 2003, The Journal of clinical investigation.
[31] P. Boelle,et al. ABCB4 gene mutation-associated cholelithiasis in adults. , 2003, Gastroenterology.
[32] B. Staels,et al. Peroxisome proliferator-activated receptor alpha (PPARalpha)-mediated regulation of multidrug resistance 2 (Mdr2) expression and function in mice. , 2003, The Biochemical journal.
[33] O. Rosmorduc,et al. MDR3 gene defect in adults with symptomatic intrahepatic and gallbladder cholesterol cholelithiasis. , 2001, Gastroenterology.
[34] P. Bosma,et al. The wide spectrum of multidrug resistance 3 deficiency: from neonatal cholestasis to cirrhosis of adulthood. , 2001, Gastroenterology.
[35] G. Hooiveld,et al. 3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors (statins) induce hepatic expression of the phospholipid translocase mdr2 in rats. , 1999, Gastroenterology.
[36] S. Cogoi,et al. Enhancement of mdr2 gene transcription mediates the biliary transfer of phosphatidylcholine supplied by an increased biosynthesis in the pravastatin‐treated rat , 1999, Hepatology.
[37] A. Rigotti,et al. Fibrates induce mdr2 gene expression and biliary phospholipid secretion in the mouse. , 1996, The Biochemical journal.
[38] K. Linton,et al. AUTOIMMUNE, CHOLESTATIC AND BILIARY DISEASE Molecular Mechanistic Explanation for the Spectrum of Cholestatic Disease Caused by the S320F Variant of ABCB4 , 2014 .